Anika Therapeutics, Inc. (ANIK) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-03-23

Key Insights

The reporting person, Ian McLeod, was granted 13,097 restricted stock units (RSUs) and 17,663 premium priced stock appreciation rights (PPSARs) on March 19, 2026, indicating ongoing alignment between management and shareholders.
The RSUs vest over time, with the first installment vesting on March 19, 2027, and the PPSARs vest in three annual installments starting on the same date, subject to the reporting person's continued service.
The exercise price of the PPSARs is set at 110% of the fair market value of the company's stock on the grant date, incentivizing the reporting person to drive long-term stock price appreciation.

Want the newest filings?

This analysis covers the filing from 2026-03-23. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-11

Insider Ian McLeod, SVP, CAO & Treasurer, exercised 2,197 restricted stock units (RSUs) and sold 639 shares to cover tax withholdings, indicating continued confidence in the company's long-term prospects.
McLeod's total beneficial ownership increased to 18,744 shares, representing a significant stake in the company and alignment with shareholder interests.
The RSU vesting schedule suggests a multi-year equity incentive program designed to retain and motivate key management, which can be viewed positively by investors.

Filed: 2026-03-11

Cheryl R. Blanchard, a director of Anika Therapeutics, Inc. (ANIK), has exercised 20,001 restricted stock units (RSUs) and disposed of 5,871 shares to cover tax withholding obligations.
Blanchard now holds a direct ownership of 211,450 shares of ANIK common stock and an indirect ownership of 11,742 shares through a revocable trust.
The transaction represents the final vesting installment of a 60,004 RSU award granted to Blanchard in March 2023, indicating continued executive involvement and commitment to the company.

Filed: 2026-03-11

The reporting person, David Colleran, is an executive (EVP, General Counsel, Corp Sec) at Anika Therapeutics, Inc. (ANIK) and is engaged in insider trading activities.
Colleran exercised 5,465 restricted stock units (RSUs) and sold 1,919 shares to cover tax withholding, indicating an ongoing equity compensation plan and insider liquidity.
Colleran now holds 53,100 shares of Anika Therapeutics, Inc. common stock, suggesting continued alignment with the company's performance.

Other reports for Anika Therapeutics, Inc.

Quarterly Report Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.